Icalcaprant not checked
AbbVie · ABBV-1354 · CVL-354
FollowEvery change as it happens, and a Monday email
Trials
2 active
7 in total
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 2
- “Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and serious illness that can cause both emotional and physical symptoms such as feelings of sadness, irritability, not being able to focus on activities, tiredness, changes in eating habits, and aches and pains. This study will assess the changes in disease activity and adverse events of oral Icalcaprant in adult participants with major depressive disorder who are currently experiencing a major depressive episode (MDE). Icalcaprant is an…”In the company’s words, NCT07276997 on ClinicalTrials.gov
- Other names
- ABBV-1354 · CVL-354
Other drugs for Major Depressive Disorder
- SeltorexantJohnson & Johnson (Janssen) · Phase 3
- AzetukalnerXenon Pharmaceuticals Inc. · Phase 3
- LumateperoneIntra-Cellular Therapies, Inc. · Phase 3
- CYB003Cybin IRL Limited · Phase 3
- Mitizodone PhosphateSunshine Lake Pharma Co., Ltd. · Phase 2/3
- OsavampatorNeurocrine Biosciences · Phase 3
Coming up2
- Sep 2027Phase 2 trial completes · ClinicalTrials.gov
- Nov 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Sep 2027 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder | |
| Phase 2Recruiting | Nov 2027 | A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | |
| Phase 1Completed | 23 Jan 2023 | A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants | |
| Phase 1Completed | 24 Jul 2024 | Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing | |
| Phase 1Completed | 13 Jan 2025 | A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Through the Body in Healthy Adult Participants | |
| Phase 1Completed | 17 Jan 2025 | A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants | |
| Phase 1Completed | 9 Dec 2025 | A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026